Update on biomarkers for amyloid pathology in Alzheimer's disease
(2018) In Biomarkers in Medicine 12(7). p.799-812- Abstract
At the center of Alzheimer's disease pathogenesis is the aberrant aggregation of amyloid-β (Aβ) into oligomers, fibrils and plaques. Effective monitoring of Aβ deposition directly in patients is essential to assist anti-Aβ therapeutics in target engagement and participant selection. In the advent of approved anti-Aβ therapeutics, biomarkers will become of fundamental importance in initiating treatments having disease modifying effects at the earliest stage. Two well-established Aβ biomarkers are widely utilized: Aβ-binding ligands for positron emission tomography and immunoassays to measure Aβ42 in cerebrospinal fluid. In this review, we will discuss the current clinical, diagnostic and research state of biomarkers for Aβ pathology.... (More)
At the center of Alzheimer's disease pathogenesis is the aberrant aggregation of amyloid-β (Aβ) into oligomers, fibrils and plaques. Effective monitoring of Aβ deposition directly in patients is essential to assist anti-Aβ therapeutics in target engagement and participant selection. In the advent of approved anti-Aβ therapeutics, biomarkers will become of fundamental importance in initiating treatments having disease modifying effects at the earliest stage. Two well-established Aβ biomarkers are widely utilized: Aβ-binding ligands for positron emission tomography and immunoassays to measure Aβ42 in cerebrospinal fluid. In this review, we will discuss the current clinical, diagnostic and research state of biomarkers for Aβ pathology. Furthermore, we will explore the current application of blood-based markers to assess Aβ pathology.
(Less)
- author
- Ashton, Nicholas J. ; Schöll, Michael LU ; Heurling, Kerstin ; Gkanatsiou, Eleni ; Portelius, Erik ; Höglund, Kina ; Brinkmalm, Gunnar ; Hye, Abdul ; Blennow, Kaj LU and Zetterberg, Henrik LU
- organization
- publishing date
- 2018-07-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, amyloid-β, Aβ, biomarkers, blood-based biomarkers, cerebrospinal fluid, dementia, positron emission tomography
- in
- Biomarkers in Medicine
- volume
- 12
- issue
- 7
- pages
- 14 pages
- publisher
- Future Medicine Ltd.
- external identifiers
-
- scopus:85049667477
- pmid:29902934
- ISSN
- 1752-0363
- DOI
- 10.2217/bmm-2017-0433
- language
- English
- LU publication?
- yes
- id
- 147e1a68-6dba-4b4a-b804-d7bd427c502e
- date added to LUP
- 2018-07-30 14:26:29
- date last changed
- 2024-09-17 00:41:26
@article{147e1a68-6dba-4b4a-b804-d7bd427c502e, abstract = {{<p>At the center of Alzheimer's disease pathogenesis is the aberrant aggregation of amyloid-β (Aβ) into oligomers, fibrils and plaques. Effective monitoring of Aβ deposition directly in patients is essential to assist anti-Aβ therapeutics in target engagement and participant selection. In the advent of approved anti-Aβ therapeutics, biomarkers will become of fundamental importance in initiating treatments having disease modifying effects at the earliest stage. Two well-established Aβ biomarkers are widely utilized: Aβ-binding ligands for positron emission tomography and immunoassays to measure Aβ42 in cerebrospinal fluid. In this review, we will discuss the current clinical, diagnostic and research state of biomarkers for Aβ pathology. Furthermore, we will explore the current application of blood-based markers to assess Aβ pathology.</p>}}, author = {{Ashton, Nicholas J. and Schöll, Michael and Heurling, Kerstin and Gkanatsiou, Eleni and Portelius, Erik and Höglund, Kina and Brinkmalm, Gunnar and Hye, Abdul and Blennow, Kaj and Zetterberg, Henrik}}, issn = {{1752-0363}}, keywords = {{Alzheimer's disease; amyloid-β; Aβ; biomarkers; blood-based biomarkers; cerebrospinal fluid; dementia; positron emission tomography}}, language = {{eng}}, month = {{07}}, number = {{7}}, pages = {{799--812}}, publisher = {{Future Medicine Ltd.}}, series = {{Biomarkers in Medicine}}, title = {{Update on biomarkers for amyloid pathology in Alzheimer's disease}}, url = {{http://dx.doi.org/10.2217/bmm-2017-0433}}, doi = {{10.2217/bmm-2017-0433}}, volume = {{12}}, year = {{2018}}, }